Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

US Epilepsy Surgery Market

ID: MRFR/HC/17816-HCR
200 Pages
Rahul Gotadki
Last Updated: April 06, 2026

US Epilepsy Surgery Market Research Report: Size, Share, Trend Analysis By Procedure Type (Respective Surgery, Laser Interstitial Thermal Therapy (LITT) and By End Users (Hospitals & Clinics, Specialty Centers) - Growth Outlook & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

US Epilepsy Surgery Market Infographic
Purchase Options
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Healthcare, BY Surgery Type (USD Million)
  49.     4.1.1 Resective Surgery
  50.     4.1.2 Functional Surgery
  51.     4.1.3 Laser Surgery
  52.     4.1.4 Hemispherectomy
  53.   4.2 Healthcare, BY Indication (USD Million)
  54.     4.2.1 Drug-resistant Epilepsy
  55.     4.2.2 Focal Epilepsy
  56.     4.2.3 Generalized Epilepsy
  57.     4.2.4 Neurodegenerative Disorders
  58.   4.3 Healthcare, BY Patient Age Group (USD Million)
  59.     4.3.1 Pediatric
  60.     4.3.2 Adult
  61.     4.3.3 Geriatric
  62.   4.4 Healthcare, BY Surgical Technique (USD Million)
  63.     4.4.1 Open Surgery
  64.     4.4.2 Minimally Invasive Surgery
  65.     4.4.3 Endoscopic Surgery
  66.   4.5 Healthcare, BY Postoperative Care (USD Million)
  67.     4.5.1 Inpatient Care
  68.     4.5.2 Outpatient Care
  69.     4.5.3 Rehabilitation Services
  70. 5 SECTION V: COMPETITIVE ANALYSIS
  71.   5.1 Competitive Landscape
  72.     5.1.1 Overview
  73.     5.1.2 Competitive Analysis
  74.     5.1.3 Market share Analysis
  75.     5.1.4 Major Growth Strategy in the Healthcare
  76.     5.1.5 Competitive Benchmarking
  77.     5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  78.     5.1.7 Key developments and growth strategies
  79.       5.1.7.1 New Product Launch/Service Deployment
  80.       5.1.7.2 Merger & Acquisitions
  81.       5.1.7.3 Joint Ventures
  82.     5.1.8 Major Players Financial Matrix
  83.       5.1.8.1 Sales and Operating Income
  84.       5.1.8.2 Major Players R&D Expenditure. 2023
  85.   5.2 Company Profiles
  86.     5.2.1 Medtronic (US)
  87.       5.2.1.1 Financial Overview
  88.       5.2.1.2 Products Offered
  89.       5.2.1.3 Key Developments
  90.       5.2.1.4 SWOT Analysis
  91.       5.2.1.5 Key Strategies
  92.     5.2.2 Boston Scientific (US)
  93.       5.2.2.1 Financial Overview
  94.       5.2.2.2 Products Offered
  95.       5.2.2.3 Key Developments
  96.       5.2.2.4 SWOT Analysis
  97.       5.2.2.5 Key Strategies
  98.     5.2.3 Abbott Laboratories (US)
  99.       5.2.3.1 Financial Overview
  100.       5.2.3.2 Products Offered
  101.       5.2.3.3 Key Developments
  102.       5.2.3.4 SWOT Analysis
  103.       5.2.3.5 Key Strategies
  104.     5.2.4 Johnson & Johnson (US)
  105.       5.2.4.1 Financial Overview
  106.       5.2.4.2 Products Offered
  107.       5.2.4.3 Key Developments
  108.       5.2.4.4 SWOT Analysis
  109.       5.2.4.5 Key Strategies
  110.     5.2.5 Stryker Corporation (US)
  111.       5.2.5.1 Financial Overview
  112.       5.2.5.2 Products Offered
  113.       5.2.5.3 Key Developments
  114.       5.2.5.4 SWOT Analysis
  115.       5.2.5.5 Key Strategies
  116.     5.2.6 NeuroPace (US)
  117.       5.2.6.1 Financial Overview
  118.       5.2.6.2 Products Offered
  119.       5.2.6.3 Key Developments
  120.       5.2.6.4 SWOT Analysis
  121.       5.2.6.5 Key Strategies
  122.     5.2.7 LivaNova (US)
  123.       5.2.7.1 Financial Overview
  124.       5.2.7.2 Products Offered
  125.       5.2.7.3 Key Developments
  126.       5.2.7.4 SWOT Analysis
  127.       5.2.7.5 Key Strategies
  128.     5.2.8 Cleveland Clinic (US)
  129.       5.2.8.1 Financial Overview
  130.       5.2.8.2 Products Offered
  131.       5.2.8.3 Key Developments
  132.       5.2.8.4 SWOT Analysis
  133.       5.2.8.5 Key Strategies
  134.     5.2.9 Epilepsy Foundation (US)
  135.       5.2.9.1 Financial Overview
  136.       5.2.9.2 Products Offered
  137.       5.2.9.3 Key Developments
  138.       5.2.9.4 SWOT Analysis
  139.       5.2.9.5 Key Strategies
  140.   5.3 Appendix
  141.     5.3.1 References
  142.     5.3.2 Related Reports
  143. 6 LIST OF FIGURES
  144.   6.1 MARKET SYNOPSIS
  145.   6.2 US MARKET ANALYSIS BY SURGERY TYPE
  146.   6.3 US MARKET ANALYSIS BY INDICATION
  147.   6.4 US MARKET ANALYSIS BY PATIENT AGE GROUP
  148.   6.5 US MARKET ANALYSIS BY SURGICAL TECHNIQUE
  149.   6.6 US MARKET ANALYSIS BY POSTOPERATIVE CARE
  150.   6.7 KEY BUYING CRITERIA OF HEALTHCARE
  151.   6.8 RESEARCH PROCESS OF MRFR
  152.   6.9 DRO ANALYSIS OF HEALTHCARE
  153.   6.10 DRIVERS IMPACT ANALYSIS: HEALTHCARE
  154.   6.11 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
  155.   6.12 SUPPLY / VALUE CHAIN: HEALTHCARE
  156.   6.13 HEALTHCARE, BY SURGERY TYPE, 2024 (% SHARE)
  157.   6.14 HEALTHCARE, BY SURGERY TYPE, 2024 TO 2035 (USD Million)
  158.   6.15 HEALTHCARE, BY INDICATION, 2024 (% SHARE)
  159.   6.16 HEALTHCARE, BY INDICATION, 2024 TO 2035 (USD Million)
  160.   6.17 HEALTHCARE, BY PATIENT AGE GROUP, 2024 (% SHARE)
  161.   6.18 HEALTHCARE, BY PATIENT AGE GROUP, 2024 TO 2035 (USD Million)
  162.   6.19 HEALTHCARE, BY SURGICAL TECHNIQUE, 2024 (% SHARE)
  163.   6.20 HEALTHCARE, BY SURGICAL TECHNIQUE, 2024 TO 2035 (USD Million)
  164.   6.21 HEALTHCARE, BY POSTOPERATIVE CARE, 2024 (% SHARE)
  165.   6.22 HEALTHCARE, BY POSTOPERATIVE CARE, 2024 TO 2035 (USD Million)
  166.   6.23 BENCHMARKING OF MAJOR COMPETITORS
  167. 7 LIST OF TABLES
  168.   7.1 LIST OF ASSUMPTIONS
  169.     7.1.1
  170.   7.2 US MARKET SIZE ESTIMATES; FORECAST
  171.     7.2.1 BY SURGERY TYPE, 2026-2035 (USD Million)
  172.     7.2.2 BY INDICATION, 2026-2035 (USD Million)
  173.     7.2.3 BY PATIENT AGE GROUP, 2026-2035 (USD Million)
  174.     7.2.4 BY SURGICAL TECHNIQUE, 2026-2035 (USD Million)
  175.     7.2.5 BY POSTOPERATIVE CARE, 2026-2035 (USD Million)
  176.   7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  177.     7.3.1
  178.   7.4 ACQUISITION/PARTNERSHIP
  179.     7.4.1

US Healthcare Market Segmentation

Healthcare By Surgery Type (USD Million, 2026-2035)

  • Resective Surgery
  • Functional Surgery
  • Laser Surgery
  • Hemispherectomy

Healthcare By Indication (USD Million, 2026-2035)

  • Drug-resistant Epilepsy
  • Focal Epilepsy
  • Generalized Epilepsy
  • Neurodegenerative Disorders

Healthcare By Patient Age Group (USD Million, 2026-2035)

  • Pediatric
  • Adult
  • Geriatric

Healthcare By Surgical Technique (USD Million, 2026-2035)

  • Open Surgery
  • Minimally Invasive Surgery
  • Endoscopic Surgery

Healthcare By Postoperative Care (USD Million, 2026-2035)

  • Inpatient Care
  • Outpatient Care
  • Rehabilitation Services

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions